Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

Reem S. Chamseddine, Shehroz Rana, Mohammed Khalid, Nicole Kucine, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2022) 140 (Supplement 1): 3999–4000.

https://doi.org/10.1182/blood-2022-168014

Published: 2022

Journal Articles

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Mohammad Alhomoud, Usama Gergis, Adrienne A. Phillips, Jingmei Hsu, Zhengming Chen, Alexandra Gomez-Arteaga, Tsiporah B. Shore, Joseph Scandura, Koen Van Besien, Sebastian A. Mayer

Blood (2022) 140 (Supplement 1): 7583–7584.

https://doi.org/10.1182/blood-2022-170097

Published: 2022

Journal Articles

JAK2 V617F Impairs T Cell Differentiation in Polycythemia Vera

Daniel C Choi, Ghaith Abu-Zeinah, Silvana Di Giandomenico, Katie Erdos, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6746–6747.

https://doi.org/10.1182/blood-2022-167785

Published: 2022

Journal Articles

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Ghaith Abu-Zeinah, Franco Castillo Tokumori, Katie Erdos, Imane Bouhali, Daniel C Choi, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6819–6820.

https://doi.org/10.1182/blood-2022-168283

Published: 2022

Journal Articles

Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis

Franco Castillo Tokumori, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2022) 140 (Supplement 1): 3993–3994.

https://doi.org/10.1182/blood-2022-170731

Published: 2022

Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 594–595.

https://doi.org/10.1182/blood-2022-159086

Published: 2022

Journal Articles

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 3961–3962.

https://doi.org/10.1182/blood-2022-170893

Published: 2022

Journal Articles

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Joseph Scandura, Srdan Verstovsek, Marina Kremyanskaya, Moshe Talpaz, Raajit K Rampal, Alessandro Vannucchi, Vikas Gupta, Francesca Palandri, Andrea Patriarca, Prithviraj Bose, Dong Chen, Oksana Zavidij, Jike Cui, Tzuu-Wang Chang, Pietro Taverna, John Mascarenhas, Claire Harrison

Blood (2022) 140 (Supplement 1): 1523–1525.

https://doi.org/10.1182/blood-2022-159409

Published: 2022

Journal Articles

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Giorgia Zanetti, Giuseppina Astone, Luca Cappelli, William Chiu, Maria Teresa Cacciapuoti, Clarisse Kayembe, Danilo Fiore, Wayne Tam, Joseph Scandura, Silvana Di Giandomenico, Lorenzo Galluzzi, Lisa Giulino Roth, Giorgio Inghirami

Blood (2021) 138 (Supplement 1): 2406.

https://doi.org/10.1182/blood-2021-151598

Published: 2021

Journal Articles

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Richard T. Silver, Elwood Taylor, III, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 2580.

https://doi.org/10.1182/blood-2021-149137

Published: 2021

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

Ghaith Abu-Zeinah, Richard T. Silver, Khalid Abu-Zeinah, Joseph Scandura

Blood (2021) 138 (Supplement 1): 2575.

https://doi.org/10.1182/blood-2021-147061

Published: 2021

Journal Articles

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Ghaith Abu-Zeinah, Spencer Krichevsky, Richard T. Silver, Elwood Taylor, III, Douglas Tremblay, Andrew Srisuwananukorn, John Mascarenhas, Joseph Scandura

Blood (2021) 138 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2021-149098

Published: 2021

Journal Articles

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Ghaith Abu-Zeinah, Silvana Di Giandomenico, Tatiana Cruz, Daniel Choi, Elwood Taylor, III, Ellen Ritchie, Richard T. Silver, Joseph Scandura

Blood (2021) 138 (Supplement 1): 627.

https://doi.org/10.1182/blood-2021-153003

Published: 2021

Journal Articles

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Blood (2021) 138 (Supplement 1): 141.

https://doi.org/10.1182/blood-2021-150172

Published: 2021

Journal Articles

Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Khalid Abu-Zeinah, Khalil Saadeh, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah

Blood (2021) 138 (Supplement 1): 235.

https://doi.org/10.1182/blood-2021-146029

Published: 2021

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Tatiana Cruz, MD, Gabriela Hoberman, BA, Niamh Savage, BA, Ellen Ritchie, MD, Joseph Scandura, MDPhD, Richard T. Silver, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141796

Published: 2020

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu Zeinah, MD, Spencer Krichevsky, BS, Diana Jaber, BA, Niamh Savage, BA, Claudia Sosner, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2019) 134 (Supplement_1): 2942.

https://doi.org/10.1182/blood-2019-130265

Published: 2019

Journal Articles

Low-Dose Epo after Tgfβ Blockade Triggers Robust Erythropoiesis and Increased RBC Production

Silvana Di Giandomenico, PhD, Ghaith Abu Zeinah, MD, Pouneh Kermani, PhD, Mia Yabut, BS, Thomas Stephens, BS, Nassima Messali, PhD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 2217.

https://doi.org/10.1182/blood-2019-129044

Published: 2019

NARROW

Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

JAK2 V617F Impairs T Cell Differentiation in Polycythemia Vera

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib

Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents

Splenomegaly (SPML) in Polycythemia Vera (PV): Its Clinical Significance and Relation to Myelofibrosis and Survival

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Normal Life Expectancy for Polycythemia Vera Patients Is Possible

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs)

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Excess Mortality in Young Patients with Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Low-Dose Epo after Tgfβ Blockade Triggers Robust Erythropoiesis and Increased RBC Production

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only